Innovative encapsulation platform based on pancreatic extracellular matrix achieve substantial insulin delivery
| Autor: | I Meivar-Levy, Limor Baruch, Marcelle Machluf, Deborah Chaimov, S Ferber, Stasia Krishtul |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine Swine medicine.medical_treatment Cellular differentiation Cell Pharmaceutical Science 02 engineering and technology Mesenchymal Stem Cell Transplantation Artificial pancreas Cell Line Diabetes Mellitus Experimental Extracellular matrix Mice 03 medical and health sciences Insulin-Secreting Cells medicine Animals Humans Insulin Cell encapsulation Cells Cultured Tissue Scaffolds Chemistry business.industry Mesenchymal stem cell Cell Differentiation Mesenchymal Stem Cells Cells Immobilized Cellular Reprogramming 021001 nanoscience & nanotechnology Extracellular Matrix Liver Transplantation Biotechnology Cell biology Mice Inbred C57BL RAW 264.7 Cells 030104 developmental biology medicine.anatomical_structure Liver Cell culture 0210 nano-technology business |
| Zdroj: | Journal of Controlled Release. 257:91-101 |
| ISSN: | 0168-3659 |
| Popis: | Cell-based therapies for the treatment of diabetes, generally aim to provide long-term glucose regulated-insulin delivery using insulin producing cells. The delivery platform is crucial for the therapeutic outcome as well as for immunoisolation of the entrapped cells. We have developed a novel artificial pancreas encapsulation platform for the treatment of diabetes that is based on solubilized whole porcine pancreatic extracellular matrix (ECM). These unique capsules were used to entrap human liver cells and mesenchymal stem cells that were induced to differentiate into glucose-regulated insulin-producing cells. We demonstrate that the ECM-microcapsule platform provides a natural fibrous 3D niche, supporting cell viability and differentiation, while significantly improving insulin delivery. In vivo, ECM-encapsulated cells were shown to be non-immunogenic, and most importantly, to significantly improve the glycemic control in diabetic mouse preclinical model, thus establishing a proof-of-concept for this new cell-based insulin delivery platform. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect